Health Check: Tetratherix breaks biotech IPO drought with 13pc gain on debut
Tetratherix's listed life starts on a solid note
Dimerix pockets a $4.2 million milestone – with close to $1.4 billion to come
Orthocell chalks up first commercial US procedure for its Remplir device
Today's ASX debut of wound management house Tetratherix (TTX) has raised the hopes of other life-science plays that have eyed an IPO but have relegated the idea to the too-hard basket.
Having downsized its offer from $35 million $25 million to banish the fast money, Tetratherix traded up to 13% above their $2.88 a share offer price.
The company has developed an injected liquid polymer that hardens at body temperature and then biodegrades after the job is done.
Yet to be approved, the platform-based tech targets novel applications including tissue healing, bone regeneration and surgical spacing (such as in prostate radiation therapy).
CEO Will Knox dubs the platform as 'medical Lego', in that the products are built from the same polymer structure.
'That means you can use the same underlying biological performance and safety data in all regulatory applications.
'Our path to market is a lot faster and simpler because the data is interchangeable across the different applications.'
Post raising, Tetratherix has cash of circa $30 million.
This factors in two US Food & Drug Administration (FDA) approval applications, one further submission and 'multiple clinical trial readouts'.
Tetratherix is the first life sciences IPO since late November 2024, when cryogenics play Vitrafy Life Sciences (ASX:VFY) and nerve repair house ReNerve (ASX:RNV) listed on the same day.
Their shares are down 20% and 50% to date, respectively.
Aptium is on IPO foot-ing
The developer of an AI-powered tool for the podiatry market, the private Aptium is eyeing an IPO after a private whip-'round.
Aptium's scanner provides real-time thermal and three and four dimensional analysis of motion and the shape of the foot.
This enables 3D manufacturing of patient-specific insoles 'with precision-grade firmness and softness:.
The tech also may detect diabetic foot ulcers early.
Co-founded by biotech greybeards Dr Mel Bridges and Carl Stubbings, Aptium is seeking to tap $5 million in a private convertible note round.
The company aspires to list within the next 18 months or so.
Bridges has founded six companies, including ImpediMed (ASX:IPD) and the formerly ASX-listed Panbio.
Stubbings was former CEO of Sienna Cancer Diagnostics, which merged with Bard1 to become Inoviq (ASX:IIQ).
Aptium could test IPO appetite in more ways than one.
That's because the company is 40% owned by Greg Creed, the former CEO of US giant Yum! Brands which owns KFC, Pizza Hut and Taco Bell.
Dimerix pockets first milestone from Japanese partner
Kidney drug developer Dimerix (ASX:DXB) has pocketed $4.2 million as its first milestone payment from Japan's Fuso, one of the company's four global partners.
Signed in January this year, the Fuso compact could deliver up to $100 million of milestone payments. This is subject to progress on Dimerix's lead phase III program, for the kidney ailment focal segmental glomerulosclerosis.
In October 2023 Dimerix inked distribution deals with the London-based Advanz Pharma (covering Europe, Canada, Australia and New Zealand).
The company followed up in May last year by entering a Middle East licensing agreement with the Oman-based pharma group, Taiba.
In its biggest deal, Dimerix last May signed up the Nasdaq-listed rare diseases house Amicus Therapeutics for the US honours.
Collectively, the deals promise $1.4 billion of potential milestones, largely contingent on eventual FDA drug approval.
The Amicus deal alone involves of US$520 million of success-based payments.
The Fuso milestone became payable on opening of the first Japanese site for the Action 3 trial.
Investors now expect likely follow-on deals in territories including China, Latin America and South Korea.
LTR Pharma is full bottle on safety study
Drug development is all about getting the small stuff right, such as whether the packaging is tickety-boo.
In this vein, LTR Pharma (ASX:LTP) has affirmed that the bottle and pump components for its proposed nasal mist based erectile dysfunctional treatment meet accepted standards.
LTR completed the so-called extractables study with co-development partner Aptar Pharma.
The study confirmed that all detected compounds met International Council for Harmonisation safety thresholds – the standard adopted by the FDA and other agencies.
A 'leachables' study is now underway, to support an FDA marketing submission.
As the name suggests, the leachables study evaluates the potential migration of compounds from packaging into the liquid.
This takes account of 'real-world' storage conditions, such as the back of the bedside drawer.
The study will run for at least 24 months, after which the company can submit its FDA entreaty.
Dubbed Spontan, LTR's treatment is based on the same active ingredient as current oral treatments but is much faster acting.
LTR is also developing Oroflow, a spray treatment for a group of ailments that affect swallowing function.
Orthocell hits the right nerve
Nerve repair play Orthocell (ASX:OCC) reports the first use of its Remplir device in a US surgical procedure, to repair a foot injury.
The FDA approved Remplir in April.
The company says the first use is a crucial step in its US rollout, 'building surgical experience and knowledge of the product that will be key in driving product sales'.
Remplir is a collagen 'wrap' that improves regeneration of damaged nerves and requires less stitching.
The surgery took place at an unnamed Ohio hospital, sourced from Orthocell's network of 14 specialist distributors.
These intermediaries have 'mature, direct-to-surgeon, hospital and other customer relationships' across 25 US states.
Orthocell CEO Paul Anderson said the critical first step in the US rollout was 'getting Remplir into surgeons' hands for them to gain familiarity with its key features and benefits in clinical practice'.
The company promises 'material' sales growth in the December half - which of course starts tomorrow – with the financial benefits reflected in the June half 2026 accounts.
Orthocell estimates that surgeons carry out two million peripheral nerve repairs annually, equating to a US$3.5 billion market.
This is across its approved markets of Australia/New Zealand, Singapore, the US, Europe/UK, Canada, Brazil, Japan, Hong Kong and Thailand.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
‘Dying in silence': Closing restaurant shares sad ‘wake-up call'
A beloved Sydney Italian restaurant – which was once booked out 'every weekend'- is set to close its doors, with its owner sharing a 'wake-up call' to Aussies as small businesses are left 'dying in silence'. Zafferano Trattoria Mediterranea, owned by Sicilian-born chef Simone Crivello and partner Isobel Galloway, has been serving up authentic Sicilian food in Paddington, in Sydney's inner-east, for over five years. But amid the cost of living crisis and climbing rents, the popular restaurant has made the difficult decision to close in August, highlighting the struggles the Sydney hospitality industry faces in a poignant video message on social media. 'Sydney, what happened to you? This used to be one of the most vibrant cities in the world,' Ms Galloway said in a video on the restaurant's Instagram page, which was not intended as a 'pity post' but rather a 'wake-up call'. 'Our restaurant was once full, bookings every night, laughter echoing through the walls, and food made with soul. Now, we're lucky if a few tables fill.' Ms Galloway acknowledged Zafferano is not the only restaurant struggling, claiming Australia is grappling with a recession. 'Small businesses are dying in silence while rent climbs, costs soar, and politicians pretend everything is fine.' 'We're in a recession, whether they wanna say it or not. People can't afford to go out. Families are struggling, somehow the government still acts like this is just a phase, but it's not. It's the reality they helped create,' she claimed. 'The economy is tanking, and the people who built this city – the chefs, the creatives, the small business owners – we're the ones paying the price.' Ms Galloway said her restaurant is having to shut not because it 'failed, but because the system did'. 'Before we go – ask yourself this. Where are you spending your money? Who are you choosing to support? And what kind of city do you want to live in?' she continued. 'Without small businesses, culture dies, community dies, and all that's left is soulless chains and boarded-up shop fronts. This isn't just a goodbye, it's a wake-up call,' she concluded. The restaurant further called on Sydneysiders to choose local and support Sydney it said has 'been left to crumble'. 'If we don't fight for what matters … there won't be anything left to fight for,' it captioned the post. Many Aussies praised Ms Galloway for highlighting the struggles many businesses continue to face. 'This makes me so sad,' one person wrote. '100% agree, we have been in a recession for about two years now,' another wrote. 'Finally someone being honest and transparent about what's really going on! Small business needs support and some tax breaks to help keep the culture alive!,' said another. Speaking to The Daily Telegraph, Ms Galloway said she and her husband, who welcomed a child in February, said they made the decision to not renew their lease after spending the last 18 months enduring the cost-of-living ciris as well as increased rent and wages. 'The past two years have been notoriously tough for hospitality,' she said. 'It's been a really tricky time and all venues have had to deal with it. But being tiny and family run, it's taken toll on us. Ms Galloway added they 'would have happily stayed in business for next 20 years but we can't afford to'. Looking to the future, the couple said they will be releasing a cookbook and plan to host food tours and open a B&B in Sicily. They will shut their doors at the end of August. NSW cafe braces for latest financial hit Zafferano isn't alone in feeling the crunch. Three Flamingos Espresso, a beloved cafe in Albion Park, near Wollongong, has been struggling with sharp increases to the cost of insurance, electricity, produce and stock – all of which has seen its profit margin shrink to a razor-thin five per cent. Owner Brad Pettitt told earlier this month he was bracing for the latest financial hit after the Fair Work Commission announced a 3.5 per cent hike to the minimum wage starting on July 1. 'Our staff work really hard and they absolutely should be rewarded, but in the context of all these other huge cost increases, it's really difficult to cope,' Mr Pettitt said. 'In the past two years, our electricity costs are up 40 per cent, gas 20 per cent, insurance and worker's comp both 10 per cent, coffee recently went up 15 per cent, bacon is up 10 per cent, and eggs, of course, the big one, is 44 per cent. 'The wage increase is modest for a few employees, but we have a staff of 24 so it all adds up to a big additional expense.' Millions of workers will see their hour rate lift to $24.95, a total of $948 per week based on 38 hours worked, up from $24.10 per hour and $915.90 per week. The Australian Industry Group estimated that the increase will see the national wages bill rise by $5 billion over the coming financial year. 'We're doing everything we can to diversify our income streams because we can't rely on day to day trade,' Mr Pettitt said. 'It's just not viable anymore.' He concedes an increase in menu prices is now inevitable. Industry groups say the larger-than-anticipated minimum wage increase will hurt vulnerable businesses, especially those in hospitality, and consumers will ultimately pay.
SBS Australia
an hour ago
- SBS Australia
Countdown on for Canada, Australia, as US tariffs loom
Countdown on for Canada, Australia, as US tariffs loom Published 30 June 2025, 8:40 am Canada says it's scrapping a proposed tax on US technology companies. It had been a flashpoint in trade negotiations between the neighbours, which now appear to be back on after the announcement. The Albanese government continues to advocate for a 10% blanket tariff to be lifted. There are also calls within the US congress for the Prime Minister to make his case in person.
AU Financial Review
2 hours ago
- AU Financial Review
Master of the market comes in from the cold
The farrago around Pointsbet's $402 million sale to Japanese social media company Mixi has drawn its fair share of rubberneckers. Computershare botched tallying the shareholder vote last week, and missed rival Betr's attempts to block the deal. Betr wants to buy Pointsbet for itself. The brainchild of the bookmaker is the country's most famous bookmaker (and Melbourne Storm chairman) Matthew Tripp. And by swallowing up the ASX-listed Blue Bet last year, Betr became a public company.
